company background image
PYFA

Pyridam Farma IDX:PYFA Stock Report

Last Price

Rp1.06k

Market Cap

Rp564.5b

7D

-1.4%

1Y

10.5%

Updated

24 May, 2022

Data

Company Financials
PYFA fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health1/6
Dividends0/6

PYFA Stock Overview

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia.

Pyridam Farma Competitors

 

 

 

 

 

 

 

 

 

 

 

 

Price History & Performance

Summary of all time highs, changes and price drops for Pyridam Farma
Historical stock prices
Current Share PriceRp1,055.00
52 Week HighRp1,325.00
52 Week LowRp930.00
Beta0.62
1 Month Change3.43%
3 Month Change4.98%
1 Year Change10.47%
3 Year Change449.48%
5 Year Change402.38%
Change since IPO276.79%

Recent News & Updates

Shareholder Returns

PYFAID PharmaceuticalsID Market
7D-1.4%-0.8%2.3%
1Y10.5%0.5%17.0%

Return vs Industry: PYFA exceeded the ID Pharmaceuticals industry which returned 1.9% over the past year.

Return vs Market: PYFA underperformed the ID Market which returned 17.3% over the past year.

Price Volatility

Is PYFA's price volatile compared to industry and market?
PYFA volatility
PYFA Average Weekly Movement4.0%
Pharmaceuticals Industry Average Movement3.7%
Market Average Movement6.2%
10% most volatile stocks in ID Market12.0%
10% least volatile stocks in ID Market2.9%

Stable Share Price: PYFA is less volatile than 75% of ID stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: PYFA's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1976895Yan Gwan Leehttps://www.pyfa.co.id

PT Pyridam Farma Tbk develops, produces, and sells pharmaceuticals, vitamins, supplements, and traditional herbal care products in Indonesia. The company operates in two segments, Pharmaceutical Products and Toll Manufacturing Services, and Medical Equipment Products. It offers medical instruments and equipment, including clinical waste, collection swab, collection tube, innerbox DCA, KF94 mask, parafilm, PCR – extraction kit and extractor machine, speciment bag, sterile container, and tube stopper.

Pyridam Farma Fundamentals Summary

How do Pyridam Farma's earnings and revenue compare to its market cap?
PYFA fundamental statistics
Market CapRp564.51b
Earnings (TTM)Rp5.48b
Revenue (TTM)Rp630.53b

103.0x

P/E Ratio

0.9x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PYFA income statement (TTM)
RevenueRp630.53b
Cost of RevenueRp385.95b
Gross ProfitRp244.58b
Other ExpensesRp239.10b
EarningsRp5.48b

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)10.24
Gross Margin38.79%
Net Profit Margin0.87%
Debt/Equity Ratio260.2%

How did PYFA perform over the long term?

See historical performance and comparison

Valuation

Is Pyridam Farma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


103.03x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate PYFA's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: PYFA is poor value based on its Price-To-Earnings Ratio (103x) compared to the ID Pharmaceuticals industry average (20.7x).

PE vs Market: PYFA is poor value based on its Price-To-Earnings Ratio (103x) compared to the ID market (18.3x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PYFA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PYFA is overvalued based on its Price-To-Book Ratio (3.4x) compared to the ID Pharmaceuticals industry average (2.5x).


Future Growth

How is Pyridam Farma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


15.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Pyridam Farma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Pyridam Farma performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


29.6%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PYFA has a high level of non-cash earnings.

Growing Profit Margin: PYFA's current net profit margins (0.9%) are lower than last year (8%).


Past Earnings Growth Analysis

Earnings Trend: PYFA's earnings have grown significantly by 29.6% per year over the past 5 years.

Accelerating Growth: PYFA's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: PYFA had negative earnings growth (-75.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (11.7%).


Return on Equity

High ROE: PYFA's Return on Equity (3.3%) is considered low.


Financial Health

How is Pyridam Farma's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: PYFA's short term assets (IDR326.4B) exceed its short term liabilities (IDR251.8B).

Long Term Liabilities: PYFA's short term assets (IDR326.4B) do not cover its long term liabilities (IDR387.3B).


Debt to Equity History and Analysis

Debt Level: PYFA's net debt to equity ratio (231.7%) is considered high.

Reducing Debt: PYFA's debt to equity ratio has increased from 24.3% to 260.2% over the past 5 years.

Debt Coverage: PYFA's debt is not well covered by operating cash flow (9.1%).

Interest Coverage: PYFA's interest payments on its debt are not well covered by EBIT (0.9x coverage).


Balance Sheet


Dividend

What is Pyridam Farma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PYFA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PYFA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PYFA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PYFA's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: PYFA is not paying a notable dividend for the ID market.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PYFA has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Yan Gwan Lee

1.75yrs

Tenure

Mr. Yan Gwan Lee serves as President Director at PT Pyridam Farma Tbk since August 14, 2020. He is a senior executive based in Indonesia and Singapore with over 25 years of working experience. He has sever...


Leadership Team

Experienced Management: PYFA's management team is considered experienced (2.6 years average tenure).


Board Members

Experienced Board: PYFA's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

PT Pyridam Farma Tbk's employee growth, exchange listings and data sources


Key Information

  • Name: PT Pyridam Farma Tbk
  • Ticker: PYFA
  • Exchange: IDX
  • Founded: 1976
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: Rp564.509b
  • Shares outstanding: 535.08m
  • Website: https://www.pyfa.co.id

Number of Employees


Location

  • PT Pyridam Farma Tbk
  • Sinarmas MSIG Tower
  • 12th Floor
  • Jakarta
  • Jakarta Raya
  • 12920
  • Indonesia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/24 00:00
End of Day Share Price2022/05/24 00:00
Earnings2021/12/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.